Xiamen Amoytop Biotech (SHA:688278) received approval from China's National Medical Products Administration for the clinical trial of ACT201 injection, according to a Shanghai bourse filing on Thursday.
The drug will be tested as a treatment for chronic hepatitis B.
The drugmaker's shares rose 3% at the close.
Coles Group (ASX:COL) lodged an appeal against the Australian Competition and Consumer Commission's (ACCC) decision to block its proposed purchase of a supermarket and liquor site in Kalgoorlie, Western Australia, according to a Wednesday filing with the Australian Competition Tribunal.Following a phase two review, the ACCC said the acquisition might materially harm competition in the retail groceries space and likely lead to the exit of an independent full-line competitor from Kalgoorlie.In its appeal, Coles said the regulator's decision was not "objectively correct or preferable."The company's shares were down nearly 1% in recent Thursday trade.
Semiconductor company Unisplendour (SHE:000938) said it will dilute its stake in subsidiary Unisplendour Computer Technology amid a 440-million-yuan capital increase.Unisplendour will waive its pre-emptive subscription rights, reducing its stake to 29.42% from 51%, with the subsidiary exiting consolidation, according to a Thursday filing with the Shenzhen bourse.One of the five investors of the capital increase, Haichen Huicai, will acquire a 12% stake in Unisplendour Computer Technology from five existing shareholders before the implementation of the capital increase.Shares of Unisplendour jumped 9% in recent trade.
WW Holdings' (TPE:8442) subsidiary, Global Worth Investment, will increase the capital of its unit, TWT Leather (Cambodia), by $2 million, bringing its total investment to $5 million, according to a Wednesday Taiwan bourse filing.The investment will be made in phases and funded through the company's funds and financial institutions.The capital increase is aimed at strengthening the unit's operating scale and expanding its production base.